Physician profile
Morgan T Orders
NPI 1962188029
$1,312.98
in general payments reported to CMS, 2019-2025
19 companies · $598 in 2025
The $598 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $238 · 2024: $477 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,312.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $213.55 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $207.09 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $196.58 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $118.35 | 2024-2025 | Rexulti |
| Pfizer INC. | $74.95 | 2023-2024 | |
| Cranial Technologies, INC | $66.98 | 2023-2024 | Doc Band |
| Bayer Healthcare Pharmaceuticals INC. | $53.86 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.84 | 2024-2025 | Jardiance, Tradjenta |
| Corcept Therapeutics | $50.00 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $43.79 | 2024-2025 | Capvaxive, Vaxelis, Gardasil 9 |
| Amgen INC. | $42.85 | 2023-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $38.36 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $33.75 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $30.24 | 2024 | Farxiga, Airsupra |
| Sanofi-Aventis U.S. LLC | $25.17 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $17.71 | 2025 | Neffy |
| Vanda Pharmaceuticals INC. | $16.87 | 2025 | Hetlioz, Fanapt |
| Corium, LLC | $16.07 | 2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.97 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Orders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.